Gilead Sciences, Inc. (NASDAQ:GILD) Receives $98.39 Consensus Target Price from Brokerages

Shares of Gilead Sciences, Inc. (NASDAQ:GILD - Get Free Report) have earned a consensus recommendation of "Moderate Buy" from the twenty-seven analysts that are covering the firm, MarketBeat.com reports. Eleven equities research analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and three have given a strong buy rating to the company. The average 12 month price objective among analysts that have covered the stock in the last year is $98.39.

Several brokerages have recently issued reports on GILD. Bank of America reaffirmed a "buy" rating and set a $109.00 price objective on shares of Gilead Sciences in a report on Tuesday, December 10th. Daiwa America raised shares of Gilead Sciences to a "hold" rating in a research note on Monday, November 18th. Wells Fargo & Company lifted their price objective on shares of Gilead Sciences from $100.00 to $105.00 and gave the stock an "overweight" rating in a research note on Thursday, November 7th. Piper Sandler upped their target price on shares of Gilead Sciences from $95.00 to $105.00 and gave the company an "overweight" rating in a research report on Thursday, November 7th. Finally, JPMorgan Chase & Co. boosted their price objective on Gilead Sciences from $105.00 to $115.00 and gave the stock an "overweight" rating in a research note on Wednesday, January 29th.

Gilead Sciences Price Performance

GILD traded down $1.61 during trading on Monday, hitting $98.04. 4,517,842 shares of the company traded hands, compared to its average volume of 6,905,398. The company has a current ratio of 1.26, a quick ratio of 1.10 and a debt-to-equity ratio of 1.24. The company has a market cap of $122.18 billion, a PE ratio of 1,089.33, a P/E/G ratio of 1.37 and a beta of 0.18. The stock's 50-day simple moving average is $92.86 and its two-hundred day simple moving average is $86.41. Gilead Sciences has a 1 year low of $62.07 and a 1 year high of $100.51.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last issued its quarterly earnings data on Wednesday, November 6th. The biopharmaceutical company reported $2.02 earnings per share for the quarter, beating analysts' consensus estimates of $1.58 by $0.44. Gilead Sciences had a return on equity of 29.00% and a net margin of 0.45%. The firm had revenue of $7.55 billion during the quarter, compared to analyst estimates of $7.01 billion. During the same quarter last year, the business posted $2.29 earnings per share. The business's quarterly revenue was up 7.0% compared to the same quarter last year. As a group, sell-side analysts anticipate that Gilead Sciences will post 4.34 earnings per share for the current fiscal year.

Insider Activity

In related news, insider Merdad Parsey sold 164,211 shares of the firm's stock in a transaction dated Wednesday, November 27th. The stock was sold at an average price of $91.92, for a total transaction of $15,094,275.12. Following the sale, the insider now owns 80,801 shares of the company's stock, valued at $7,427,227.92. This trade represents a 67.02 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Director Jeffrey Bluestone sold 6,788 shares of the business's stock in a transaction dated Tuesday, November 26th. The stock was sold at an average price of $91.39, for a total transaction of $620,355.32. Following the completion of the transaction, the director now owns 8,920 shares of the company's stock, valued at $815,198.80. This represents a 43.21 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 572,824 shares of company stock worth $53,611,715. Corporate insiders own 0.29% of the company's stock.

Hedge Funds Weigh In On Gilead Sciences

Institutional investors and hedge funds have recently bought and sold shares of the company. nVerses Capital LLC purchased a new position in Gilead Sciences during the 3rd quarter worth $25,000. HHM Wealth Advisors LLC boosted its holdings in Gilead Sciences by 118.5% in the fourth quarter. HHM Wealth Advisors LLC now owns 284 shares of the biopharmaceutical company's stock worth $26,000 after acquiring an additional 154 shares in the last quarter. Valued Wealth Advisors LLC grew its stake in shares of Gilead Sciences by 101.9% during the third quarter. Valued Wealth Advisors LLC now owns 319 shares of the biopharmaceutical company's stock worth $27,000 after acquiring an additional 161 shares during the last quarter. YANKCOM Partnership acquired a new position in shares of Gilead Sciences during the fourth quarter valued at about $28,000. Finally, Decker Retirement Planning Inc. purchased a new position in shares of Gilead Sciences in the 4th quarter valued at approximately $29,000. 83.67% of the stock is owned by hedge funds and other institutional investors.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.